CD274 and non-small cell lung carcinoma: The third highly-cited article, authored by Martin Reck (Reck et al., 2016) and also published in the New England Journal of Medicine, noted that in patients with advanced NSCLC exhibiting PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with considerably longer PFS and OS and with fewer adverse effects than for the platinum-based treatment.